Даваа–Баасан 08:30–20:00 · Бямба 09:00–16:00
Now showing 1 - 4 of 4
  • Some of the metrics are blocked by your 
    Item type:Publication,
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Impact of IDH1 Mutation on Long-Term Survival in Patients with Diffuse Glioma
    (Mongolian National University of Medical Sciences, 2019-03-31)
    Enkhee Ochirjav
    ;
    ;
    Gheeyoung Choe
    ;
    Objectives: Diffuse brain gliomas are common primary brain tumor associated with a poor prognosis. In this study, we aimed to determine the impact of IDH1 mutation status on long term survival. Methods: Patients who underwent surgery for diffuse brain glioma were selected. Based on IDH1 mutation status, patients were separated into IDH1 mutant and IDH1 wildtype groups. Results: A total of 124 patients with diffuse brain tumor were included (mean age 39±17, 48.4% male). The frequency of IDH1 mutant and IDH1 wildtype were 56.5% (n=70) and 43.5% (n=54), respectively. During follow-up, 76 patients (61.3%) died and the median follow-up was 8 months (IQR 4; 16). Patients with IDH1 mutant more likely younger (36±16 vs. 43±17, p<.05) and had low grade (grade II) tumor (64.3% vs. 20.4%, p<.001). After adjustment of possible predictors, such age, gender, tumor location and surgical type, IDH1 mutant was an independent predictor of all-cause mortality (HR=0.43, 95% CI 0.26- 0.71, p<.001). Kaplan-Meier estimation showed IDH1 mutant is associated with longer survival compared with IDH1 wildtype in low grade tumor (log rank p<.001). Conclusion: Mutated IDH1 is an independent predictor of all-cause mortality in patients with diffuse brain glioma and resulted in longer survival compared with IDH1 wildtype.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Prognostic Value of Immunohistochemical Biomarkers in Patients with Astrocytic Brain Tumor
    (Mongolian National University of Medical Sciences, 2018-09-25)
    Enkhee Ochirjav
    ;
    Bolortuya Dorj
    ;
    ;
    Objectives: Astrocytoma is a common primary malignant brain tumor and it is typically associated with poor outcome. In this study, we aimed to determine role of various immunohistochemical (IHC) biomarkers and their relationship with patient prognosis. Methods: Patients who underwent surgery for astrocytic brain tumor were selected. Tissue specimens were collected from surgically removed tumors and stained by various IHC stains. All-cause mortality was chosen for study endpoint. Results: A total of 133 patients with who underwent surgery for astrocytic brain tumor were included (mean age 38±19 and 49.6% male). During follow-up, 84 patients (63%) died and the median time of death was 8 months (IQR 4; 16) after hospital discharge. Patients who died had higher tumor grade (60.7% vs. 34.7%, p<0.01). After adjustment of possible predictors, surgical type (HR=0.51, 95% CI 0.31-0.82, p<0.01), expression level of Ki67 (HR=1.02, 95% CI 1.00-1.04, p<0.05) and p53 (HR=1.01, 95% CI 1.00-1.02, p<0.05) were independently associated with long term mortality. Kaplan-Meier estimation showed overexpression of WT1 (42% vs. 52%, p<0.05) and Ki67 (27% vs. 58%, p<0.001) are associated with poor survival. Conclusion: IHC biomarkers are independently associated with long term prognosis in patients with astrocytic brain tumor. Overexpression of WT1 and Ki67 marker are associated with poor survival.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Reclassification of Mongolian Diffuse Gliomas According to the Revised 2016 World Health Organization Central Nervous System Tumor Classification
    (The Korean Society of Pathologists and The Korean Society for Cytopathology, 2019-09)
    Ochirjav, Enkhee
    ;
    ; ;
    Choe, Gheeyoung
    BACKGROUND: The 2016 World Health Organization (WHO) classification of central nervous system (CNS) tumors has been modified to incorporate the IDH mutation and 1p/19q co-deletion in the diagnosis of diffuse gliomas. In this study, we aimed to evaluate the feasibility and prognostic significance of the revised 2016 WHO classification of CNS tumors in Mongolian patients with diffuse gliomas. METHODS: A total of 124 cases of diffuse gliomas were collected, and tissue microarray blocks were made. IDH1 mutation was tested using immunohistochemistry, and 1p/19q co-deletion status was examined using fluorescence in situ hybridization analysis. RESULTS: According to the 2016 WHO classification, 124 cases of diffuse brain glioma were reclassified as follows: 10 oligodendroglioma, IDHmut and 1p/19q co-deleted; three anaplastic oligodendroglioma, IDHmut and 1p/19q co-deleted; 35 diffuse astrocytoma, IDHmut, 11 diffuse astrocytoma, IDHwt, not otherwise specified (NOS); 22 anaplastic astrocytoma, IDHmut, eight anaplastic astrocytoma, IDHwt, NOS; and 35 glioblastoma, IDHwt, NOS, respectively. The 2016 WHO classification presented better prognostic value for overall survival in patients with grade II tumors than traditional histological classification. Among patients with grade II tumors, those with oligodendroglioma IDHmut and 1p/19q co-deleted and diffuse astrocytoma IDHmut showed significantly higher survival than those with diffuse astrocytoma IDHwt, NOS (p<.01). CONCLUSIONS: Mongolian diffuse gliomas could be reclassified according to the new 2016 WHO classification. Reclassification revealed substantial changes in diagnosis of both oligodendroglial and astrocytic entities. We have confirmed that the revised 2016 WHO CNS tumor classification has prognostic significance in Mongolian patients with diffuse gliomas, especially those with grade II tumors.
    Scopus© Citations 2